Refractory Angina Market - Size and Forecast [2021-2031]
The Refractory Angina Market is expected to register a CAGR of 10.0% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX million by 2031.
The report is segmented by Refractory Angina Market By Drugs ( Estrogen, Nicorandil, Ivabradibe, Ranolazine and L-arginine ); Therapies ( Enhanced External Counterpulsation and Transcutaneous Electrical Nerve Stimulation), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Refractory Angina Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Refractory Angina Market Segmentation
By Drugs- Estrogen
- Nicorandil
- Ivabradibe
- Ranolazine and L-arginine
- Enhanced External Counterpulsation and Transcutaneous Electrical Nerve Stimulation
Strategic Insights
Refractory Angina Market Growth Drivers- Increasing Incidence of Refractory Angina: One of the main factors influencing market demand is the prevalence of refractory angina. About 5% to 15% of people with angina pectoris have it, therefore many patients need efficient care techniques. Refractory angina is predicted to become more common as the population ages and coronary artery disease survival rates increase, necessitating the development of novel therapeutic approaches.
- Growing Geriatric population: The number of elderly people worldwide is growing quickly, which is increasing the frequency of refractory angina cases linked to aging. It is anticipated that 80 percent of the elderly would live in low- and middle-income nations by 2050, which will raise the need for refractory angina products even more. Thus, increase in number of geriatric population is anticipated to drive the growth of market.
- Growing demand for Research and Development: The market is expanding due to a strong pipeline of clinical trials concentrating on therapies for refractory angina. Innovative treatments that target myocardial ischemia, which is essential for treating refractory angina, are being developed by businesses like Caladrius Biosciences and Angionetics Inc. The possible approval of these novel treatments has the potential to improve patient outcomes and have a substantial impact on treatment paradigms.
- Technological Advancements: The refractory angina industry is being greatly impacted by recent advancements in treatment approaches. Novel treatments include enhanced external counterpulsation (EECP), spinal cord stimulation, and coronary sinus reduction are showing promise. These innovative methods are intended to help patients who don't react to traditional treatments by reducing their symptoms and enhancing their quality of life. More individuals looking for treatment from persistent chest discomfort are anticipated as a result of the launch of these medicines.
- Healthcare Policies: Better access to refractory angina diagnostic and treatment options can be made possible by government policies that support cardiovascular health. The management landscape for refractory angina can be improved by initiatives that concentrate on supporting research into chronic illnesses and upgrading healthcare infrastructure, which will propel market growth.
- Addressing Unmet Medical Needs: Many people with coronary artery disease who do not improve with standard therapy suffer from refractory angina. Targeting the underlying ischemia mechanisms, stem cell treatment offers a novel strategy that may alleviate symptoms and enhance quality of life. These medications pave the way for addressing the significant unmet need for efficient treatments in this patient population since they exhibit promise in clinical trials.
- Clinical Evidence Supporting Efficacy: Stem cell treatment has been shown in recent meta-analyses to improve clinical outcomes for individuals with refractory angina. For instance, research has demonstrated that individuals getting stem cell treatments have improved left ventricular ejection fraction, decreased anginal episodes, and increased exercise capacity when compared to those receiving a placebo. Such proof increases trust in these treatments and promotes their use, which propels market expansion.
- Innovation and Research Investment: Significant research and development expenditures have been made in the market for refractory angina as a result of the increased interest in stem cell therapy. Businesses are actively investigating a variety of stem cell types, including CD34-positive cells, which have demonstrated encouraging outcomes in enhancing myocardial perfusion and lowering significant adverse cardiac events. More money and resources will probably enter the market as a result of this emphasis on cutting-edge treatments.
- Potential for New Treatment Paradigms: Treatment paradigms for refractory angina may change as stem cell technologies show promise. By combining cell-based therapies with already available pharmaceutical choices, the introduction of these innovative medicines may result in a more thorough approach to addressing the condition. This possible change could increase the number of therapy options available to medical professionals and enhance patient outcomes.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Refractory Angina Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Refractory Angina Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Budgetary Constraints
Europe region is expected to witness a high growth rate in terms of CAGR after Asia Pacific region during the forecast period
Asia Pacific region is expected to witness the highest growth during the forecast period
Rising Incidence of refractory angina
The Refractory Angina Market is estimated to witness a CAGR of 10.0% from 2023 to 2031
Clinical Evidence Supporting Efficacy
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Refractory Angina Market - By Drugs
1.3.2 Refractory Angina Market - By Therapies
1.3.3 Refractory Angina Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. REFRACTORY ANGINA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. REFRACTORY ANGINA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. REFRACTORY ANGINA MARKET - GLOBAL MARKET ANALYSIS
6.1. REFRACTORY ANGINA - GLOBAL MARKET OVERVIEW
6.2. REFRACTORY ANGINA - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. REFRACTORY ANGINA MARKET - REVENUE AND FORECASTS TO 2028 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. ESTROGEN
7.3.1. Overview
7.3.2. Estrogen Market Forecast and Analysis
7.4. NICORANDIL
7.4.1. Overview
7.4.2. Nicorandil Market Forecast and Analysis
7.5. IVABRADIBE
7.5.1. Overview
7.5.2. Ivabradibe Market Forecast and Analysis
7.6. RANOLAZINE AND L-ARGININE
7.6.1. Overview
7.6.2. Ranolazine and L-arginine Market Forecast and Analysis
8. REFRACTORY ANGINA MARKET - REVENUE AND FORECASTS TO 2028 - THERAPIES
8.1. OVERVIEW
8.2. THERAPIES MARKET FORECASTS AND ANALYSIS
8.3. ENHANCED EXTERNAL COUNTERPULSATION AND TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION.
8.3.1. Overview
8.3.2. Enhanced External Counterpulsation and Transcutaneous Electrical Nerve Stimulation. Market Forecast and Analysis
9. REFRACTORY ANGINA MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Refractory Angina Market Overview
9.1.2 North America Refractory Angina Market Forecasts and Analysis
9.1.3 North America Refractory Angina Market Forecasts and Analysis - By Drugs
9.1.4 North America Refractory Angina Market Forecasts and Analysis - By Therapies
9.1.5 North America Refractory Angina Market Forecasts and Analysis - By Countries
9.1.5.1 United States Refractory Angina Market
9.1.5.1.1 United States Refractory Angina Market by Drugs
9.1.5.1.2 United States Refractory Angina Market by Therapies
9.1.5.2 Canada Refractory Angina Market
9.1.5.2.1 Canada Refractory Angina Market by Drugs
9.1.5.2.2 Canada Refractory Angina Market by Therapies
9.1.5.3 Mexico Refractory Angina Market
9.1.5.3.1 Mexico Refractory Angina Market by Drugs
9.1.5.3.2 Mexico Refractory Angina Market by Therapies
9.1.5.4 US Refractory Angina Market
9.1.5.4.1 US Refractory Angina Market by Drugs
9.1.5.4.2 US Refractory Angina Market by Therapies
9.2. EUROPE
9.2.1 Europe Refractory Angina Market Overview
9.2.2 Europe Refractory Angina Market Forecasts and Analysis
9.2.3 Europe Refractory Angina Market Forecasts and Analysis - By Drugs
9.2.4 Europe Refractory Angina Market Forecasts and Analysis - By Therapies
9.2.5 Europe Refractory Angina Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Refractory Angina Market
9.2.5.1.1 Germany Refractory Angina Market by Drugs
9.2.5.1.2 Germany Refractory Angina Market by Therapies
9.2.5.2 France Refractory Angina Market
9.2.5.2.1 France Refractory Angina Market by Drugs
9.2.5.2.2 France Refractory Angina Market by Therapies
9.2.5.3 Italy Refractory Angina Market
9.2.5.3.1 Italy Refractory Angina Market by Drugs
9.2.5.3.2 Italy Refractory Angina Market by Therapies
9.2.5.4 Spain Refractory Angina Market
9.2.5.4.1 Spain Refractory Angina Market by Drugs
9.2.5.4.2 Spain Refractory Angina Market by Therapies
9.2.5.5 United Kingdom Refractory Angina Market
9.2.5.5.1 United Kingdom Refractory Angina Market by Drugs
9.2.5.5.2 United Kingdom Refractory Angina Market by Therapies
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Refractory Angina Market Overview
9.3.2 Asia-Pacific Refractory Angina Market Forecasts and Analysis
9.3.3 Asia-Pacific Refractory Angina Market Forecasts and Analysis - By Drugs
9.3.4 Asia-Pacific Refractory Angina Market Forecasts and Analysis - By Therapies
9.3.5 Asia-Pacific Refractory Angina Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Refractory Angina Market
9.3.5.1.1 Australia Refractory Angina Market by Drugs
9.3.5.1.2 Australia Refractory Angina Market by Therapies
9.3.5.2 China Refractory Angina Market
9.3.5.2.1 China Refractory Angina Market by Drugs
9.3.5.2.2 China Refractory Angina Market by Therapies
9.3.5.3 India Refractory Angina Market
9.3.5.3.1 India Refractory Angina Market by Drugs
9.3.5.3.2 India Refractory Angina Market by Therapies
9.3.5.4 Japan Refractory Angina Market
9.3.5.4.1 Japan Refractory Angina Market by Drugs
9.3.5.4.2 Japan Refractory Angina Market by Therapies
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Refractory Angina Market Overview
9.4.2 Middle East and Africa Refractory Angina Market Forecasts and Analysis
9.4.3 Middle East and Africa Refractory Angina Market Forecasts and Analysis - By Drugs
9.4.4 Middle East and Africa Refractory Angina Market Forecasts and Analysis - By Therapies
9.4.5 Middle East and Africa Refractory Angina Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Refractory Angina Market
9.4.5.1.1 South Africa Refractory Angina Market by Drugs
9.4.5.1.2 South Africa Refractory Angina Market by Therapies
9.4.5.2 Saudi Arabia Refractory Angina Market
9.4.5.2.1 Saudi Arabia Refractory Angina Market by Drugs
9.4.5.2.2 Saudi Arabia Refractory Angina Market by Therapies
9.4.5.3 U.A.E Refractory Angina Market
9.4.5.3.1 U.A.E Refractory Angina Market by Drugs
9.4.5.3.2 U.A.E Refractory Angina Market by Therapies
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Refractory Angina Market Overview
9.5.2 South and Central America Refractory Angina Market Forecasts and Analysis
9.5.3 South and Central America Refractory Angina Market Forecasts and Analysis - By Drugs
9.5.4 South and Central America Refractory Angina Market Forecasts and Analysis - By Therapies
9.5.5 South and Central America Refractory Angina Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Refractory Angina Market
9.5.5.1.1 Brazil Refractory Angina Market by Drugs
9.5.5.1.2 Brazil Refractory Angina Market by Therapies
9.5.5.2 Argentina Refractory Angina Market
9.5.5.2.1 Argentina Refractory Angina Market by Drugs
9.5.5.2.2 Argentina Refractory Angina Market by Therapies
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. REFRACTORY ANGINA MARKET, KEY COMPANY PROFILES
11.1. ARK THERAPEUTICS GROUP PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NEOVASC INC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. SANERON CCEL THERAPEUTICS, INC
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. VASOMEDICAL, INC
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. CRYOPRAXIS
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. WORKHARDT
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. SYNOKEM
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. GRANDIX PHARMACEUTICALS
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. BLUECROSS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. VIRGINIA SPINE INSTITUTE
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
- Ark Therapeutics Group plc
- Neovasc Inc
- Saneron CCEL Therapeutics, Inc
- Vasomedical, Inc
- Cryopraxis
- Workhardt
- Synokem
- Grandix Pharmaceuticals
- Bluecross
- Virginia Spine Institute
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For